0
My cart

Choose your region, country/territory, and preferred language

rhAmpSeq™ CRISPR Analysis System

Reviewer-ready, NGS-based on- and off-target confirmation—no bioinformatics expertise required.
Analyze your edits in your own lab or let IDT handle the analysis for you. Uniform amplification enables simultaneous coverage of hundreds of target sites, making it easy to assess edit quality with confidence

Need help with your analysis?

Whether you’d like IDT to perform your on or off-target analysis for you or you simply have questions, our CRISPR experts are happy to help.

Advanced, accessible, and rapid CRISPR analysis

snapshot of the rhampseq crispr analysis tool

Quantify your editing results in under a week with four easy steps:

1
Design & order
Upload your list of on- and off-target CRISPR edit sites into the rhAmpSeq design tool for automated library design. We offer off target nomination services if you need help.
2
Library prep & sequence

When your custom rhAmpSeq reagents arrive, follow the provided easy steps to build your rhAmpSeq multiplexed amplicon library, then sequence with Illumina-based NGS.

3
Easy analysis

Upload your FASTQ files into the rhAmpSeq analysis portal for automated analysis of each edit site.

“IDT’s rhAmpSeq technology allows us to quickly and accurately quantify CRISPR genome editing off-target frequencies cost-effectively in our preclinical studies."

Dr. Ayal Hendel

Associate Professor
Bar-Ilan University

workflow for rhamp library preparation

Harness the power of rhAmp PCR

Create amplicon libraries with only two PCRs. Our rhAmp technology leverages the intrinsic properties of RNase H2 and RNA-base–containing blocked primers to minimize primer dimers and enable high-fidelity multiplexing.

RUO26-4210_001

CGMP gRNA products are manufactured in accordance with ICH Q7, 21CFR210, 211, and parts of 600. IDT engineering runs and CGMP gRNA are for development and investigational use only. The performance characteristics of this product have not been established.  This product is not intended to be used as final drug product. The purchaser is solely responsible for all decisions regarding the intended use of the product and any associated legal or regulatory obligations.